PubMed Journals Articles About "Secukinumab Showed Sustained Improvements After Years" RSS

21:30 EDT 23rd September 2018 | BioPortfolio

Secukinumab Showed Sustained Improvements After Years PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Secukinumab Showed Sustained Improvements After Years articles that have been published worldwide.

More Information about "Secukinumab Showed Sustained Improvements After Years" on BioPortfolio

We have published hundreds of Secukinumab Showed Sustained Improvements After Years news stories on BioPortfolio along with dozens of Secukinumab Showed Sustained Improvements After Years Clinical Trials and PubMed Articles about Secukinumab Showed Sustained Improvements After Years for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Secukinumab Showed Sustained Improvements After Years Companies in our database. You can also find out about relevant Secukinumab Showed Sustained Improvements After Years Drugs and Medications on this site too.

Showing "Secukinumab showed sustained improvements after years" PubMed Articles 1–25 of 32,000+

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study).

Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis.

Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.

Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab shoul...

Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study.

The ACCESS-model offers integrated care including assertive community treatment to patients with psychotic disorders. ACCESS proved more effective compared to standard care (ACCESS-I study) and was successfully implemented into clinical routine (ACCESS-II study). In this article, we report the 4-year outcomes of the ACCESS-II study. Between May 2007 and December 2013, 115 patients received continuous ACCESS-care. We hypothesized that the low 2-year disengagement and hospitalization rates and significant imp...

Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.

To evaluate improvement in pain and fatigue in ankylosing spondylitis (AS) patients treated with secukinumab over 2 years (MEASURE 2 study).

Could antiretrovirals be treating EBV in MS? A case report.

We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV...

Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.

Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.

Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.

Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C virus (HCV) in patients with psoriasis who are receiving secukinumab therapy. This multicentre study screened 284 patients with psoriasis with available HBV and HCV serological data and 63 patients with concurrent HBV/HCV infection were enrolled. In the absence of antiviral prophylaxis, 7 of 46 (15.2%) patients with HB...

Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.

Treatment with tumor necrosis factor-α inhibitors has been reported to cause weight gain in patients with psoriasis; however, limited information is available in terms of the effects of interleukin (IL)-23 and IL-17A inhibitors on bodyweight (BW) in patients with psoriasis. This study aimed to investigate the effects of infliximab, ustekinumab and secukinumab on BW and body mass index (BMI) in patients with psoriasis. We retrospectively examined changes in BW and BMI among patients treated with these biolo...

Sustained quality-of-life improvements over 10 years after deep brain stimulation for dystonia.

Little is known about the quality of life of people with dystonia and DBS beyond 5 years. The objectives of this study were (1) to examine the long-term quality-of-life outcomes in a large cohort of people with dystonia and DBS, (2) to determine the incidence of stimulation-induced parkinsonism, and (3) to elucidate the potential long-term cognitive impact of DBS in this cohort.

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.

Juvenile generalized pustular psoriasis (GPP) is rare and often resistant to conventional systemic therapy such as methotrexate, retinoic acid and cyclosporin A. GPP can be induced by deficiency of interleukin (IL)-36 receptor antagonist (DITRA). No standardized guidelines are available for juvenile GPP or DITRA, and a uniformly safe and effective biologic agent has not been identified. However, multiple biologics approved for use in plaque-type psoriasis have also been used in GPP. Herein, we report a case...

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.

Understanding genetic variations is important in predicting the treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for the treatment of psoriasis. Limited data are available for the efficacy of secukinumab in relation to genetic markers.

Real-life efficacy and safety of secukinumab: Results from a tertiary hospital in Greece.

Secukinumab is a recombinant monoclonal antibody that prevents interleukin 17A (IL-17A) from binding to its receptor, thus limiting inflammatory processes ultimately leading to excessive keratinocyte proliferation. According to phase-III clinical trials, it significantly reduces disease severity within a short period of time (PASI75>80% at week 12). Three real-life studies (47, 69 & 83 patients each) showed that 72.30%, 52.90% & 80.00% of treated subjects respectively achieved PASI75 at week 12. Still, more...

Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol.

The objective of this systematic review is to synthesize current evidence on the effectiveness of pharmacotherapy as compared to all comparators for the management of pseudobulbar affect in adults 16 years and over who have sustained a traumatic brain injury. The specific review question is: What is the effectiveness of pharmacotherapy for the management of pseudobulbar affect in adults 16 years and over who have sustained a traumatic brain injury?

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations.

Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: A 12-week, multicenter, retrospective study.

A recent review by Hu et al. highlights the use of biologic switching in clinical practice to maximize skin clearance and improve clinical outcomes. However, efficacy and safety outcomes of ixekizumab therapy in patients who did not respond to, lost response, or were intolerant to secukinumab was not mentioned in their review and is lacking. As such, dermatologists may be hesitant to switch between interleukin (IL)-17A antagonists, electing to try an alternative biologic with a different mechanism of actio...

Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata.

Alopecia areata (AA) is a common form of non-scarring hair loss. The pathogenesis of AA is believed to involve multiple inflammatory cytokines, including possibly IL-17A. To assess the efficacy and safety of the IL-17A antagonist secukinumab in AA, we conducted a double-blinded, randomized prospective pilot study in which 11 subjects were treated with either secukinumab (n = 7) or placebo (n = 4) subcutaneously at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter until (inclusive of) week 20. The pr...

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.

To evaluate the efficacy and safety of secukinumab 150 mg, with or without a loading regimen, using a self-administered prefilled syringe in patients with ankylosing spondylitis (AS) over 104 weeks from the MEASURE 4 study.

Secukinumab decreases the serum KL-6 level in psoriasis patients with elevated serum KL-6 level.

Several papers reported that tumor necrosis factor (TNF)-α inhibitors such as adalimumab (ADA) induced interstitial pneumonia (IP) in patients with rheumatoid arthritis . We here retrospectively investigated the changes in serum KL-6 levels, which should be elevated in patient with IP , in psoriasis patients receiving secukinumab (SEC), anti-interleukin (IL)-17A antibody, in addition to patients receiving ADA. This article is protected by copyright. All rights reserved.

Prefrontal Modulation of Visual Processing and Sustained Attention in Aging, a Transcranial Direct Current Stimulation-Electroencephalogram Coregistration Approach.

The ability to sustain attention is integral to healthy cognition in aging. The right PFC (rPFC) is critical for maintaining high levels of attentional focus. Whether plasticity of this region can be harnessed to support sustained attention in older adults is unknown. We used transcranial direct current stimulation to increase cortical excitability of the rPFC, while monitoring behavioral and electrophysiological markers of sustained attention in older adults with suboptimal sustained attention capacity. Du...

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab.

Iodine adequacy in Tasmania sustained after 7 years of mandatory bread fortification.

Cognitive improvement in first-episode schizophrenia and healthy controls: A 6-year multi-assessment follow-up study.

The development of individual cognitive domains over time is not yet fully examined in first-episode schizophrenia (FES). This study's objective was to explore the cognitive trajectories of FES-patients (n = 28) and compare them to a pairwise matched healthy control group (n = 28, total n = 56). This study has a multi-assessment design, and includes patient data from seven assessments over six years. Healthy controls were assessed at baseline, after two years and after six years. Cognition was a...

Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece.

Secukinumab is an anti-IL17A antibody approved for the treatment of moderate-to-severe plaque psoriasis since 2015. After 52 weeks of a 300 mg monthly dosage, 78.20-84.30% of patients maintained PASI75 in clinical trials. Efficacy seems to be less well maintained in real life, however, as 60-74% and 53.80-78% of biologic naïve and non-naïve patients respectively, as well as 68.30-80% of patients regardless of prior treatment, had PASI75 at week 52. This article is protected by copyright. All rights reser...

A study of cadmium remediation and mechanisms: Improvements in the stability of walnut shell-derived biochar.

Biochar has been recognized as an efficient soil amendment for cadmium remediation in recent years. In the present study, biochar was prepared using walnut shell, and it was incubated in Cd(NO) and kaolin for 15 days. Different chemical forms of cadmium in kaolin and biochar were determined, and the stability of biochar was evaluated by R using TGA analysis. It was found that walnut shell derived biochar could reduce the mobility of cadmium. After incubation, the R value increased from 61.31% to 69.57%-72...

Large-Scale Social and Behavior Change Communication Interventions Have Sustained Impacts on Infant and Young Child Feeding Knowledge and Practices: Results of a 2-Year Follow-Up Study in Bangladesh.

Sustained improvements in infant and young child feeding (IYCF) require continued implementation of effective interventions. From 2010-2014, Alive & Thrive (A&T) provided intensive interpersonal counseling (IPC), community mobilization (CM), and mass media (MM) in Bangladesh, demonstrating impact on IYCF practices. Since 2014, implementation has been continued and scaled up by national partners with support from other donors and with modifications such as added focus on maternal nutrition and reduced progra...

Quick Search